Kornimate/medical-research-clean huggingface dataset:
brief admission skane: replacing general admission for individuals with self-harm and acute risk of suicide

Conditions: Self-Injurious Behavior; Suicidal Ideation; Suicide, Attempted; Borderline Personality Disorder; Emergency Services, Psychiatric

Summary: the purpose of the study is to test a standardized version of brief admission (ba) through randomized controlled trial (rct). the main objective is to evaluate if ba can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of borderline personality disorder. participants will be allocated to ba + treatment as usual (tau) or tau.

when individuals with recurrent self-harm and suicidal behaviour seek acute admission to hospital due to a crisis and associated increased suicidal ideation, recommendations for clinical care are still conflicting. the risk for iatrogenic effects of inpatient care are considerable, and long hospital admissions without a clear treatment structure may predict decompensation in functioning. this has resulted in a clinical practice of avoiding admission for individuals diagnosed with borderline personality disorder (bpd). brief admission (ba) as an intervention has a longstanding history in the delivery of mental health services in the netherlands. the core elements of brief admission were determined through consultation with dutch researchers, interviews with individuals with experience, dutch clinicians familiar with brief admission, and local guidelines from hospitals familiar with implementing this crisis management intervention. core elements of the intervention were standardized into a protocol, and an educational manual was developed to train clinicians involved in the trial. an objectively rated fidelity measure was developed in order to ensure adherence.

Eligibility criteria:
inclusion criteria: * current episodes of self-harm and/or recurrent suicidality. * fulfilling at least three criteria for borderline personality disorder. * admitted to psychiatric hospital for acute care for at least 7 days or presenting to the psychiatric emergency department at least 3 times during the last six months. exclusion criteria: * no regular contact with outpatient psychiatric services. * homelessness. housing crises are outside the scope of this rct. * medical disorder from other organs that significantly contributes to inclusion criteria (e.g. if self-harm only occurs during episodes of hypoglycemia in a diabetic patient).

Keywords: brief admission admission deliberate self-harm self-harm
using beta blockers to treat mitral regurgitation

Conditions: Heart Disease; Mitral Regurgitation; Heart Valve Disease; Mitral Valve Insufficiency

Summary: the purpose of this study tests whether beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation.

the purpose of this study tests 1) whether toprol xl, a beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation; 2) investigate the effects of chronic mitral regurgitation on left ventricular remodeling, left ventricular function,exercise capacity and clinical symptoms.

Eligibility criteria:
inclusion criteria: * diagnosis of sever primary mitral regurgitation * normal subjects exclusion criteria: * left ventricle ejection fraction of \<55% pre and post operation * pregnancy or lactation * secondary mitral regurgitation due to coronary artery disease, cardiomyopathy, uncontrolled hypertension, or severe aortic stenosis.

Keywords: heart disease mitral regurgitation heart valve disease mitral valve insufficiency heart surgery heart valve surgery
long-term follow-up of anterior cruciate ligament injury

Conditions: Anterior Cruciate Ligament Injury

Summary: anterior cruciate ligament (acl) rupture is one of the most common sports-related knee injuries. because it is such a significant injury - requiring a long period of rehabilitation before the injured person is ready to return to physical activity, the burden of injury is high. this can help to explain why so much of orthopaedic research is devoted to evaluating the outcomes of acl injury. however, while there has been extensive study of short-term (up to 5 years after injury) outcomes, few studies have followed patients beyond 15 years after their acl injury. this is important because long-term follow-up can provide key insights to guide the information provided to newly injured patients (e.g. to help set realistic expectations of what the injured person can expect of their knee function in the future), and help us evaluate the efficacy of previous treatments. the primary aim is to assess the influence of an acute acl injury on knee function and quality of life, 32-37 years after the index injury. approximately 300 patients injured between 1980 and 1985 will be invited to participate in the study. patient- and clinician-reported outcomes, and radiographic osteoarthritis will be evaluated.

patients injuring their acl between 1980 and 1985 have periodically been followed since the injury. now, we plan to contact all patients and invite them to participate. the patients will be asked to 1. complete a questionnaire battery 2. visit the movement laboratory at linköping university for an objective assessment of knee function and 3. have an x-ray of both knee joints. baseline information including associated injuries, treatment and activity level exist for all the patients. at that time, rehabilitation was normally completed after 4-6 months for non-operatively treated patients, and nine months after acl surgery.

Eligibility criteria:
inclusion criteria: * primary acl injury between 1980 and 1985, age between 15 and 40 at injury exclusion criteria: * all patients from the initial cohort will be invited for participation
study of intraductal carboplatin in women with ductal carcinoma in situ (dcis)

Conditions: Ductal Carcinoma In Situ

Summary: the primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on day 1 or twice on days 1 and 15 in women with ductal carcinoma in situ (dcis) undergoing surgical management 2 to 4 weeks following the day 15 intraductal infusion. secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on mri and mammogram, histopathological assessment of dcis, and biomarker measurement of ki-67, tunel and g-actin.

this is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of dcis. forty-five (45) women who have been diagnosed with dcis by core biopsy will receive intraductal administration of either carboplatin or normal saline (ns) into the dcis-involved breast duct. thirty (30) patients (i.e., 15 patients per arm) will receive two intraductal infusions of either 100 mg of carboplatin or ns on days 1 and 15. fifteen (15) patients will receive an intraductal infusion of 100 mg carboplatin on day 1 and an intraductal infusion of ns on day 15. patients will undergo surgical resection 2 to 4 weeks following the day 15 intraductal infusion (i.e. 4 to 6 weeks from diagnosis). the effect of carboplatin on dcis in the pre-treatment core biopsy specimen and the resection specimen will be assessed. venous blood samples will be collected for carboplatin pk analysis pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on days 1 and 15.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * scheduled to undergo surgical resection in 2 weeks or longer * pathological diagnosis of dcis requiring surgical resection * dcis diagnosed with core biopsy * mammogram within 6 weeks of diagnosis * adequate organ function as defined by the following criteria: absolute neutrophil count (anc) ≥ 1500/μl, platelets ≥ 140,000/μl,hemoglobin ≥ 12.0 g/dl, creatinine \< 2.0 mg/dl - able to sign informed consent exclusion criteria: * current diagnosis of invasive or inflammatory breast carcinoma * dcis with microinvasion on histology on core needle biopsy * palpable mass * mass on mammography * concurrent anti-cancer therapy * prior exposure to carboplatin (related to current or past diagnosis) * prior radiation to the breast or chest wall * prior areolar or breast surgery which interrupts communication of the ductal systems with the nipple * presence of breast implants * presence of ulcerating or fungal skin lesions or infection of the breasts * pregnant or lactating * impaired cardiac function or history of cardiac problems * poor nutritional state (as determined by clinician) * presence of serious infection * scheduled for intraoperative radiation of breast or chest wall * allergies to lidocaine or marcaine * allergies to imaging dyes

Keywords: ductal carcinoma in situ dcis breast cancer carboplatin intraductal
brisk walk on chronic obstructive pulmonary disease

Conditions: COPD

Summary: to determine the effects of 30 min brisk walk on pulmonary functions on copd patients to determine the effects of 30 min brisk walk on health related health-related quality of life (hrlq) on chronic obstructive pulmonary disease (copd) patients


Eligibility criteria:
inclusion criteria: * copd patients (gold criteria mild and moderate). exclusion criteria: * dyspnea more than 4 * walking issues * rheumatoid arthritis * musculoskeletal disorder * acute infections.

Keywords: aerobic exercise brisk walk health-related quality of life
comparison of immunogenicity and reactogenicity of infanrix™ hexa and hexavac™ vaccines as a primary vaccination course

Conditions: Hepatitis B; Poliomyelitis; Diphtheria; Acellular Pertussis; Tetanus; Haemophilus Influenzae Type b

Summary: the study will compare the immunogenicity and the reactogenicity of infanrix™ hexa and hexavac™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.


Eligibility criteria:
inclusion criteria: * a healthy male or female subject between 8 and 15 weeks of age at the time of the first vaccination. * written informed consent obtained from the parent or guardian of the subject prior to the study entry. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * born after a normal gestation period between 36 and 42 weeks. exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period. * evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis b and/or hib vaccination or disease. * planned administration of a vaccine not foreseen by the study protocol since birth and during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose of the three-dose primary vaccination course, with the exception of licensed neisseria meningitides conjugate vaccines or bacillus calmette-guérin (bcg) vaccine that can be given in between study visits or after the third visit, provided they are given preferably with a 4 weeks interval but not less than 3 weeks apart from the study vaccine doses. * chronic administration or planned administration of immuno-suppressants or other immune-modifying drugs since birth. * planned administration of immunoglobulins and/or any blood products since birth or planned administration during the period up to 30 days after the third dose of the primary vaccination course. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * history of seizures, progressive neurological disease or intra-cerebral haemorrhage. * major congenital defects or serious chronic illness. * acute febrile illness at the time of planned vaccination * history of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.

Keywords: hexavactm infanrixtm hexa dtpa-hbv-ipv-hib dtpa-hbv-ipv/hib
a multi-center registry study: the follow-up the complications for trans-vaginal mesh surgery

Conditions: Pelvic Organ Prolapse

Summary: this is a multi-center, prospective, observational, hospital-based registry of pelvic organ prolapse(pop) patients who having trans-vaginal mesh implantation with 12 month and 36 month follow-up.to investigate the incidence of postoperative complications according to the international urogynecological association/international continence society (iuga/ics) complication classification system(the category- time-site(cts) coding).

patients who undergo pelvic floor reconstructive surgery with trans-vaginal mesh for the cure of pelvic organ prolapse (pop) between june 2019 and december 2022 from 41 centers across the country are going to be prospectively collected. the study is designed to report the clinical data，outcomes and complications of transvaginal mesh surgery in china. the information gathered will identify the incidence rate of complications, especially mesh exposure/erosion, in chinese women and whether published, professional guidelines on pop surgical treatment as well as mesh complications management are being applied appropriately. findings from this registry may help in knowing the current status of transvaginal mesh use in china as well as identify issues that may affect the surgical outcome and complications occurrence. based on the registry study, clinical practice on the management of transvaginal mesh implantation including selection patients, pre- and post-operative evaluation and complications surgical database will be established. the follow-up process starts after patients have completed the operation; thus, our study does not affect patients' choice of surgical method.

Eligibility criteria:
inclusion criteria: 1） patients who undergo the pelvic reconstruction surgery with trans-vaginal mesh; 2) patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation; 3）willing to participate in 36 months of longitudinal follow-up and able to provide written informed consent. willing to provide an email address and complete questionnaires on we-chat, either in clinic or elsewhere when they have access to the internet. exclusion criteria: * 1) currently pregnant at enrollment; * 2) physically or mentally unable to participate in up to 36 months of follow-up; * 3) desires other surgical management of pop other than trans-vaginal mesh.

Keywords: trans-vaginal mesh pelvic reconstruction surgery complications the cts(category-time-site) coding system
gatt versus canaloplasty (gvc)

Conditions: Glaucoma, Open-Angle

Summary: study aims to compare the effectiveness and safety profile of gonioscopy-assisted transluminal trabeculotomy and canaloplasty, in order to find out if one operation is superior to the other. both procedures are performed in patients with medically uncontrolled open-angle glaucoma. canaloplasty is a recently newly introduced procedure, which showed encouraging results without antimetabolite usage intra- and postoperatively. gonioscopy-assisted transluminal trabeculotomy is the procedure that aims the same mechanism of aqueous outflow, however is perform with ab interno approach, which comprise it to the minimally invasive glaucoma surgery techniques. purpose of the study is to compare both surgeries concerning success rate, intraocular pressure, medication burden and complications rate. so far there is no comparison of the gonioscopy-assisted transluminal trabeculotomy and canaloplasty available.


Eligibility criteria:
inclusion criteria: * 18 years and older (adult, older adult) * patients with confirmed uncontrolled open angle glaucoma * no prior glaucoma surgery (once laser trabeculoplasty or cyclophotocoagulation) allowed exclusion criteria: * angle closure glaucoma * congenital glaucoma * inflammatory glaucoma

Keywords: gonioscopy-assisted transluminal trabeculotomy canaloplasty glaucoma
the pharmacogenetics of optimal warfarin therapy in chinese patients after heart valve replacement.

Conditions: Heart Valve Disease; Older Than 18-years-old; Without Any Liver or Kidney Diseases

Summary: to value the accuracy of the dosing algorithm published by the international warfarin pharmacogenetics consortium in chinese patients after heart valve replacement. to value the accuracy of warfarin pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the chinese patients.

the dosing algorithm published by the international warfarin pharmacogenetics consortium hadn't been verifying by a standard randomized prospective study in chinese patients after heart valve replacement. and, warfarin will affect people's coagulation, so that probably increase the drainage. we'll analyse the interaction of patients' pt-inr or drainge and oral warfarin dosing.

Eligibility criteria:
inclusion criteria:atrial fibrillation * atrial fibrillation * heart valve replacement * vte exclusion criteria: * severe liver or kidney diseases

Keywords: warfarin chinese patients heart valve replacement
individualizing dose of growth hormone to maintain normal growth velocity after fulfilled catch up growth in children

Conditions: Short Stature

Summary: the objective was to study whether normal growth velocity can be maintained with adapted gh dosage in gh treated prepubertal children who have responded to gh treatment with fulfilled catch up growth (=difference to target height reached, less than - 0.6 sds).

the aim of the trial is to study the effect of adapted gh treatment in order to find an individualized gh dose maintaining normal growth velocity close to target height sds and normal metabolism after fulfilled catch up growth in prepubertal children treated with individual doses of gh within the trial 98-0198-003 (1). the overall aim is to find for the individual the lowest effective gh dose during maintenance period, maintaining normal growth velocity and metabolism, i.e. a satisfactory biological active dose.

Eligibility criteria:
inclusion criteria: * participated in the 'gh-dose catch-up study' 98- 0198-003. * midparental height reached (difference less than 0.6 sds) * prepubertal at start of the study (girls =b 1, boys: testes :\<; 3ml). * signed written informed consent from the patient's parents (and the child if old enough) exclusion criteria: * disease affecting growth other than correctly treated hypothyroidism. * incapable of following the study protocol (i.e. bad compliance in the previous study). * puberty (\> breast stage 2, or testes \> 4ml). * poor compliance.

Keywords: treatment growth hormone childhood short stature
validity and cost-effectiveness of a new screening test for hepatocellular carcinoma

Conditions: Hepatitis B Virus

Summary: the purpose of this study is: 1. to establish and compare the diagnostic utilities for hepatocellular carcinoma (hcc) screening tests of (a) hs-afp, (b) afp + us,(c) afp alone and (d) us alone (within hbv carriers between age 40 and 70 years); 2. to establish the cost-effectiveness of the screening tests; 3. to compare tumor sizes, resection rates, and survival rates up to 18 months between those who were screened by hs-afp those of a historical control group that was not screened.


Eligibility criteria:
inclusion criteria: * age between 40 and 70 years * seropositive for hbsag * child's a or b * life expectancy of more than 2 years exclusion criteria: * non-hbv related cirrhosis * history of malignancy

Keywords: hbv carriers
tracking mood: the effects of daily mood tracking vas on alcohol consumption in adult heavy drinkers

Conditions: Alcohol Abuse; Alcohol Drinking; Alcohol Use Disorder; Alcohol Dependence; Alcohol Intoxication

Summary: the study aims to investigate the effects that mood tracking may have on the alcohol consumption of adults who consume more than 20 uk units of alcohol per week, classifying as high-risk drinkers. the intervention group will track their mood on a daily basis with a visual analogue scale, while the control group will report their daily time spent online. the hypothesis, based on a series of prior pilot studies on alcohol tracking methods, is that mood tracking can reduce alcohol consumption in high-risk drinkers and therefore be a suitable addition to interventions related to decreasing alcohol consumption in heavy drinkers. the study will be conducted online through the prolific platform.

participants will be recruited through prolific. all participants will complete a series of demographic and psychometric questionnaires before beginning the study. participants will also complete some of the psychometric questionnaires (rcq, gad-7, phq-9) at the end of the study to track any potential changes. participants will be pre-screened for their motivation using a modified mtss (motivation to stop smoking) scale. participants will also be asked to report their primary source of motivation regarding wanting to quit or reduce drinking, in addition to reporting their main goal regarding alcohol, where the options will be wanting to quit, wanting to reduce drinking, wanting to be more in control of their drinking, and not wanting to quit, reduce, or be more in control of drinking. all participants will also report their alcohol consumption using a timeline followback task with the ability to view both a calendar and a reference image of uk alcohol units. they'll report their alcohol consumption from the week before the study and complete two tlfbs during the study. intervention group participants complete daily visual analogue scales of their mood. control group participants complete daily reports of how many hours they spent online the previous day.

Eligibility criteria:
inclusion criteria: * speaking fluent english * being over 18 years of age * high completion rates of previous studies on the prolific platform * being located in the united kingdom * consuming over 20 uk units of alcohol per week exclusion criteria: * having an ongoing mental health condition

Keywords: alcohol aud mood tracking ema emotional monitoring alcohol tracking
fibroblast specific inhibition of loxl2 and tgfbeta1 signaling in patients with pulmonary fibrosis.

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this is a two part study. in the first part, the pharmacokinetic profile of epigallocatechin-3-gallate (egcg) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. in the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with egcg will be evaluated in biochemical assays and compared to samples from untreated control patients.

this is an interventional study intended to test inhibition of a signaling pathway in vivo in patients with interstitial lung disease, but not intended to affect lung function or disease modifications. doses of oral epigallocatechin-3-gallate (egcg) that achieve plasma levels known to be safe in human volunteers and likely to target fibroblast tgfbeta ri kinase will be established. disposable fragments of biopsies will be evaluated in biochemical assays including psmad3 and snail 1 or assayed to determine lysyl oxidase-like 2 (loxl2) protein and loxl2 enzyme activity. urine collected before and after egcg exposure will be used to determine whether terminal collagen cross-link breakdown products, termed pyridinoline/deoxypyridinoline (pyd/dpd) are changed from baseline. blood collected before and after egcg exposure will be assayed for serum biomarkers.

Eligibility criteria:
inclusion criteria: * part 1: healthy volunteers * part 2: * study will consist of patients presenting to the ucsf interstitial lung disease (ild) outpatient clinic with imaging indicative of lung fibrosis but of uncertain classification, and who are willing to take egcg for a minimum of 2 weeks prior to surgery. exclusion criteria: * co-morbidities affect hepatic function, such as hcv infection, cirrhosis, or * using drugs with significant hepatic toxicities